Cited by 342Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

The FDA's Assessment of Two Drugs for Chronic Weight Management

Colman, Eric, Golden, Julie, Roberts, Mary, Egan, Amy, Weaver, Joyce, Rosebraugh, Curtis·2012·New England Journal of Medicine

DOI 10.1056/nejmp1211277

Open this paper in CoChat — free account

Abstract

After weighing the risks and benefits, the FDA recently approved two new drugs as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management in obese or overweight adults with at least one weight-related coexisting condition.

Integrity signals

Registry

Crossref · 10.1056/nejmp1211277

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP)
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 565
Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study
O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012) · Obesity · doi:10.1038/oby.2012.66 · Cited by 525
The Obesity Epidemic and Its Impact on Hypertension
Nguyen, T., & Lau, D. C. W. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.01.001 · Cited by 223
Use of topiramate in pregnancy and risk of oral clefts
Margulis, A. V., Mitchell, A. A., Gilboa, S. M., Werler, M. M., Mittleman, M. A., Glynn, R. J., & Hernández–Dı́az, S. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.07.008 · Cited by 178
Serotonergic drugs and valvular heart disease
Rothman, R. B., & Baumann, M. H. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902931524 · Cited by 144
Obesity and type 2 diabetes: which patients are at risk?
Garber, A. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01536.x · Cited by 114

Show all 13 references

Sorted by citations

Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Phentermine and topiramate for the management of obesity: a review
Uwaifo, G. I., Cosentino, & Conrad, A. O. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s31443 · Cited by 242
Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis
Berglund, E. D., Liu, C., Sohn, J., Liu, T., Kim, M. H., Lee, C. E., Vianna, C. R., Williams, K. W., Xu, Y., & Elmquist, J. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70338 · Cited by 232
Locally Induced Adipose Tissue Browning by Microneedle Patch for Obesity Treatment
Zhang, Y., Liu, Q., Yu, J., Yu, S., Wang, J., Qiang, L., & Gu, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b04348 · Cited by 229
Obesity and reproduction: a committee opinion
Penzias, A. S., Azziz, R., Bendikson, K. A., Falcone, T., Hansen, K. R., Hill, M. J., Jindal, S., Kalra, S. K., Mersereau, J. E., Reindollar, R. H., et al. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.08.018 · Cited by 246
Obesity and reproduction: a committee opinion
(2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.08.018 · Cited by 219
The anti-obesity effect of green tea polysaccharides, polyphenols and caffeine in rats fed with a high-fat diet
Xü, Y., Zhang, M., Wu, T., Dai, S., Xu, J., & Zhou, Z. (2014) · Food & Function · doi:10.1039/c4fo00970c · Cited by 210
Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy
Veiby, G., Daltveit, A. K., Engelsen, B. A., & Gilhus, N. E. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7239-x · Cited by 196
Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles
Xue, Y., Xu, X., Zhang, X., Farokhzad, O. C., & Langer, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603840113 · Cited by 189
Pharmacotherapy of Obesity: Clinical Treatments and Considerations
Holes-Lewis, K., Malcolm, R. J., O'Neil, P. M., & Hermayer, K. L. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828abcfd · Cited by 188
Obesity: Current and potential pharmacotherapeutics and targets
Narayanaswami, V., & Dwoskin, L. P. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 188
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 176
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168
Lifestyle intervention in childhood obesity: changes and challenges
Reinehr, T. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.149 · Cited by 169
Safety of antiobesity drugs
Cheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613489721 · Cited by 163
Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
Sharretts, J., Galescu, O., Gomatam, S., Andraca-Carrera, E., Hampp, C., & Yanoff, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2003873 · Cited by 147
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Son, J. W., & Kim, S. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0258 · Cited by 155
Adipose tissue: friend or foe?
Hassan, M. S., Latif, N., & Yacoub, M. H. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.148 · Cited by 146
Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management
Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182937 · Cited by 136
Priming with Whole-Cell versus Acellular Pertussis Vaccine
Liko, J., Robison, S. G., & Cieslak, P. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1212006 · Cited by 128
The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options
Fani, L., Bak, S., Delhanty, P., van Rossum, E. F. C., & van den Akker, E. L. T. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.80 · Cited by 121
Peripheral Serotonin: a New Player in Systemic Energy Homeostasis
Namkung, J., Kim, H., & Park, S. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0258 · Cited by 121
Medical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
Use of prescription antiobesity drugs in the United States.
Hampp, C., Kang, E. M., & Borders‐Hemphill, V. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1342 · Cited by 103
From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists
Higgins, G. A., Sellers, E. M., & Fletcher, P. J. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.001 · Cited by 100
Weight management in obesity – past and present
Haslam, D. B. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12771 · Cited by 107
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy
Fujioka, K., Plodkowski, R. A., O'Neil, P. M., Gilder, K. M., Walsh, B., & Greenway, F. L. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.67 · Cited by 90
Nuciferine, an active ingredient derived from lotus leaf, lights up the way for the potential treatment of obesity and obesity-related diseases
Wan, Y., Xia, J., Xu, J., Chen, L., Yang, Y., Wu, J., Tang, F., Ao, H., & Peng, C. Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106002 · Cited by 87
The role of prolactin in andrology: what is new?
Rastrelli, G., Corona, G., & Maggi, M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9322-3 · Cited by 87
2014 EASO Position Statement on the Use of Anti-Obesity Drugs
Toplak, H., Woodward, E., Yumuk, V., Oppert, J., Halford, J. C. G., & Frühbeck, G. (2015) · Obesity Facts · doi:10.1159/000430801 · Cited by 83
The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Higgins, G. A., Fletcher, P. J., & Shanahan, W. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107417 · Cited by 80
Epigenetic Regulation of Adipogenesis in Development of Metabolic Syndrome
Pant, R., Firmal, P., Shah, V. K., Alam, A., & Chattopadhyay, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.619888 · Cited by 83
Pharmacological strategies for targeting BAT thermogenesis
Whittle, A. J., Relat, J., & Vidal‐Puig, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.004 · Cited by 82
Tolerability and Safety of the New Anti-Obesity Medications
Hainer, V., & Aldhoon-Hainerová, I. (2014) · Drug Safety · doi:10.1007/s40264-014-0206-3 · Cited by 76
Molecular and Neural Functions of Rai1 , the Causal Gene for Smith-Magenis Syndrome
Huang, W., Guenthner, C. J., Xu, J., Nguyen, T., Schwarz, L. A., Wilkinson, A. W., Gozani, O., Chang, H. Y., Shamloo, M., & Luo, L. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.019 · Cited by 74
Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies
Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21140 · Cited by 72
Update on obesity pharmacotherapy
Bray, G. A., & Ryan, D. H. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12328 · Cited by 88
Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity
Chung, H., Yu, J. G., Lee, I., Liu, M., Shen, Y., Sharma, S. P., Jamal, M. A. H. M., Yoo, J., Kim, H., & Hong, S. (2015) · FEBS Open Bio · doi:10.1002/2211-5463.12024 · Cited by 68
Obesity and Black Women: Special Considerations Related to Genesis and Therapeutic Approaches
Agyemang, P., & Powell‐Wiley, T. M. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0328-7 · Cited by 63
Dibenzazepine-Loaded Nanoparticles Induce Local Browning of White Adipose Tissue to Counteract Obesity
Jiang, C., Cano-Vega, M. A., Yue, F., Kuang, L., Narayanan, N., Uzunallı, G., Merkel, M. P., Kuang, S., & Deng, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.020 · Cited by 66
Pharmacotherapy for Patients with Obesity
Gadde, K. M., Apolzan, J. W., & Berthoud, H. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.272815 · Cited by 57
Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration
Unett, D. J., Gatlin, J., Anthony, T. L., Buzard, D. J., Chang, S., Chen, C., Xiaohua, C., Dang, H. T., Frazer, J. M., Le, M. K., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.207670 · Cited by 56
Why are anti-obesity drugs stigmatized?
Halpern, B., & Halpern, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.995088 · Cited by 55
The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
Mancini, M. C., & de Melo, M. E. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0242-0 · Cited by 58
miR-21 mimic blocks obesity in mice: A novel therapeutic option
Lhamyani, S., Gentile, A., Giráldez‐Pérez, R. M., Feijoo‐Cuaresma, M., Romero‐Zerbo, S., Clemente‐Postigo, M., Zayed, H., Oliva‐Olivera, W., Bermúdez‐Silva, F. J., Salas, J., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.019 · Cited by 55
Prescriber's Guide
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275 · Cited by 52
Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications
Halpern, B., & Halpern, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.994502 · Cited by 51
Luteolin reduces fat storage in Caenorhabditis elegans by promoting the central serotonin pathway
Yan, L., Yang, N., Bao, B., Wang, L., Chen, J., & Liu, J. (2019) · Food & Function · doi:10.1039/c9fo02095k · Cited by 49
Nanotechnology‐Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities
Tsou, Y., Wang, B., Ho, W., Hu, B., Tang, P. L., Sweet, S., Zhang, X., & Xu, X. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801184 · Cited by 50
The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases
Nonogaki, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031600 · Cited by 49
Heart Failure and Obesity: Translational Approaches and Therapeutic Perspectives. A Scientific Statement of the Heart Failure Association of the ESC
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 52
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice
Gadde, K. M., & Raj, Y. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0859-2 · Cited by 49
Precision Medicine in Weight Loss and Healthy Living
Severin, R. S., Sabbahi, A., Mahmoud, A. M., Arena, R. A., & Phillips, S. A. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.12.012 · Cited by 47
Pharmacologic Treatment Options for Obesity: What Is Old Is New Again
Ryan, D. H., & Bray, G. A. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0343-6 · Cited by 42
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release
Halpern, B., & Mancini, M. C. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1247807 · Cited by 42
Oolong tea polysaccharide and polyphenols prevent obesity development in Sprague–Dawley rats
Wu, T., Xu, J., Chen, Y., Liu, R., & Zhang, M. (2018) · Food & Nutrition Research · doi:10.29219/fnr.v62.1599 · Cited by 42
Combination phentermine and topiramate extended release in the management of obesity.
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041505 · Cited by 38
Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a Novel Peripherally Restricted Cannabinoid-1 Receptor Antagonist with Significant Weight-Loss Efficacy in Diet-Induced Obese Mice
Chang, C., Wu, C.-H., Song, J., Chou, M., Wong, Y., Lin, Y., Yeh, T., Sadani, A. A., Ou, M., Chen, K.-H., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401158e · Cited by 37
Lifestyle Management for Enhancing Outcomes after Bariatric Surgery
Kalarchian, M., Turk, M., Elliott, J., & Gourash, W. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0540-y · Cited by 36
Vascular risk in obesity: Facts, misconceptions and the unknown
King, R., & Ajjan, R. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116675488 · Cited by 39
Fluoxetine for adults who are overweight or obese
Serralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Meléndez, G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011688.pub2 · Cited by 36
Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit
Cunningham, J. W., & Wiviott, S. D. (2014) · Clinical Cardiology · doi:10.1002/clc.22304 · Cited by 35
Lorcaserin for the treatment of obesity? A closer look at its side effects
DiNicolantonio, J. J., Chatterjee, S., O’Keefe, J. H., & Meier, P. (2014) · Open Heart · doi:10.1136/openhrt-2014-000173 · Cited by 35
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy
Milano, W., Biasio, V. D., Munzio, W. D., Foggia, G., & Capasso, A. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200515112853 · Cited by 33
Drugs for Treating Obesity
Ryan, D. H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_560 · Cited by 37
New Pharmacological Treatments for the Management of Obesity
Hurt, R. T., Varayil, J. E., & Ebbert, J. O. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0394-0 · Cited by 33
Role of impulsivity and reward in the anti-obesity actions of 5-HT 2C receptor agonists
Higgins, G. A., Zeeb, F. D., & Fletcher, P. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117735797 · Cited by 34
Obesity an overview: Genetic conditions and recent developments in therapeutic interventions
Rao, V., Candasamy, M., & Bhattamisra, S. K. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.004 · Cited by 33
Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice
PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Patel, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0189 · Cited by 32
Serotonin Transporter Binding in the Diencephalon Is Reduced in Insulin-Resistant Obese Humans
Versteeg, R. I., Koopman, K. E., Booij, J., Ackermans, M. T., Unmehopa, U. A., Fliers, E., la Fleur, S. E., & Serlie, M. J. M. (2016) · Neuroendocrinology · doi:10.1159/000450549 · Cited by 32
Directly Observable Behavioral Effects of Lorcaserin in Rats
Serafine, K. M., Rice, K. C., & France, C. P. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228148 · Cited by 31
Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review
Conde, K., Fang, S., & Xu, Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01091-7 · Cited by 33
Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index ≥27 kg/m2
Davidson, M. H., Tonstad, S., Oparil, S., Schwiers, M., Day, W. W., & Bowden, C. H. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.038 · Cited by 31
GUCY2C: at the intersection of obesity and cancer
Kim, G. W., Lin, J. E., & Waldman, S. A. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.001 · Cited by 31
Lorcaserin: A Review of its Use in Chronic Weight Management
Hoy, S. M. (2013) · Drugs · doi:10.1007/s40265-013-0035-1 · Cited by 31
Barriers and Solutions for Prescribing Obesity Pharmacotherapy
Fujioka, K., & Harris, S. R. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.007 · Cited by 27
Metabolic Benefits of MicroRNA-22 Inhibition
Thibonnier, M., & Esau, C. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0820 · Cited by 27
Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats
Gannon, B. M., Sulima, A., Rice, K. C., & Collins, G. T. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246082 · Cited by 26
Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease
Yang, Y., Huang, H., Xu, Z., & Duan, J. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7680576 · Cited by 25
Patient Characteristics Associated with Receipt of Prescription Weight‐Management Medications Among Veterans Participating in MOVE!
Thomas, D. D., Waring, M. E., Ameli, O., Reisman, J. I., & Vimalananda, V. G. (2019) · Obesity · doi:10.1002/oby.22503 · Cited by 25
Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice
Gadde, K. M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.890590 · Cited by 26
Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes
Ottney, A. R. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130081 · Cited by 26
Neuropeptide receptors as potential pharmacological targets for obesity
Meneguetti, B. T., Cardoso, M. H. E. S., Ribeiro, C. F. A., Felício, M. R., Pinto, I. B., Santos, N. C., Carvalho, C. M. E., & Franco, O. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.002 · Cited by 23
Phentermine
Lim, S., Rogers, L. K., Tessler, O., Mundinger, G. S., Rogers, C. L., & Lau, F. H. (2018) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000001478 · Cited by 20
Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review
Serralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Meléndez, G. (2022) · Obesity Facts · doi:10.1159/000524995 · Cited by 25
The effect of antiobesity drugs on waist circumference: a mixed treatment comparison
Chilton, M., Dunkley, A. J., Carter, P., Davies, M. J., Khunti, K. K., & Gray, L. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12198 · Cited by 19
Lorcaserin for weight management
Taylor, J., Dietrich, E. A., & Powell, J. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s36276 · Cited by 20
Obesity and type 2 diabetes: can we find a compromised treatment solution?
Galstyan, G. R., Shestakova, E. A., & Sklyanik, I. A. (2017) · Diabetes Mellitus · doi:10.14341/dm8726 · Cited by 21
Antiobesity Pharmacotherapy for Patients with Type 2 Diabetes: Focus on Long-Term Management
Jeon, W. S., & Park, C.-Y. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.410 · Cited by 18
Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones
Behary, P., Cegla, J., Tan, T., & Bloom, S. R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1048181 · Cited by 17
Obesity Management of Liver Transplant Waitlist Candidates and Recipients
Brandman, D. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.08.001 · Cited by 21
In vitro structure–activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety–depression model
Lewellyn, K., Białońska, D., Loria, M. J., White, S. W., Sufka, K. J., & Zjawiony, J. K. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.011 · Cited by 17
Effects of resistant dextrin for weight loss in overweight adults: a systematic review with a meta-analysis of randomized controlled trials
Mukai, J., Tsuge, Y., Yamada, M., Otori, K., & Atsuda, K. (2017) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-017-0084-9 · Cited by 17
Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
The interaction between nutrition and the brain and its consequences for body weight gain and metabolism; studies in rodents and men
la Fleur, S. E., & Serlie, M. J. M. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.06.001 · Cited by 16
Gαi/o-coupled Htr2c in the paraventricular nucleus of the hypothalamus antagonizes the anorectic effect of serotonin agents
Yoo, E.-S., Li, L., Jia, L., Lord, C. C., Lee, C. E., Birnbaum, S. G., Vianna, C. R., Berglund, E. D., Cunningham, K. A., Xu, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109997 · Cited by 15
Treating the obese diabetic
Kenkre, J. S., Tan, T., & Bloom, S. R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.5 · Cited by 14
Unexpected Reaction Pathway for butyrylcholinesterase-catalyzed inactivation of “hunger hormone” ghrelin
Yao, J., Yuan, Y., Zheng, F., & Zhan, C. (2016) · Scientific Reports · doi:10.1038/srep22322 · Cited by 15

Authors: Colman, E., Golden, J., Roberts, M., Egan, A., Weaver, J., & Rosebraugh, C.
Affiliations: United States Food and Drug Administration (US)
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-10-25
Volume: 367
Issue: 17
Pages: 1577-1579
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmp1211277
OpenAlex: W2331430051
Cited by: 342
References: 13
Citations by year: 2026: 4 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 14 · 2020: 162 · 2019: 11 · 2018: 7 · 2017: 17 · 2016: 18 · 2015: 22 · 2014: 24 · 2013: 42 · 2012: 3
FWCI: 21.58
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords: chronic weight management, obesity, overweight adults, FDA drug approval, anti-obesity drugs, adjunctive therapy, hypocaloric diet, physical activity, comorbidities, risk-benefit assessment
MeSH terms: Abnormalities, Drug-Induced, Topiramate, Benzazepines, Delayed-Action Preparations, Drug Combinations, Female, Fructose, Humans, Obesity, Phentermine, Pregnancy, United States, United States Food and Drug Administration, Weight Loss, Drug Approval, Serotonin Receptor Agonists, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The FDA's Assessment of Two Drugs for Chronic Weight Management

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks